Loading…
← CockpitCompetitor Analysis › BSLN.SW Basilea Pharmaceutica AGOpen in the cockpit ↗

Basilea Pharmaceutica AGBSLN.SWCompetitor analysis, valuation and peers

Switzerland · CHF·Health Care›Pharmaceuticals: Major

Swiss biopharma selling antifungal and antibacterial hospital drugs, led by Cresemba and Zevtera.

≈ A small Swiss anti-infectives specialistMomentum leader 87
Mkt cap
$1.04B
US dollars, full cap
Free float
92%
of shares outstanding
$/day
$2.98M
20-day average traded
Fwd P/E
10.5×
forward earnings
ROIC−WACC
+63.0 pp
WACC 5.0%
Hurdle
-18 pp
Req g minus delivered
Next earnings
90 days
16 Feb 2027
Close · CHFCHF 71.50
1D-0.6%
1W+0.7%
1M+5.9%
3M+10.7%
6M+33.4%
YTD+30.7%
1Y+52.6%
ATR %3.0%
52w lowhigh5.7% off high

What Basilea Pharmaceutica does

Swiss biopharma selling antifungal and antibacterial hospital drugs, led by Cresemba and Zevtera.

Much of the income comes as royalties and milestone payments from licensing partners that market Cresemba in their regions, plus supply of the drug to them, rather than from its own sales force. Zevtera follows a similar route through regional distributors.

In one line: A small Swiss anti-infectives specialist.

Products and services

  • Cresemba (isavuconazole) - antifungal
  • Zevtera (ceftobiprole) - antibacterial
  • Pipeline (oncology, anti-infectives)

Customers

  • Hospitals
  • Licensing partners (regional distributors)

Where it sits in the supply chain

  • Biopharmaceuticals
  • Anti-infectives
  • Antifungal & antibacterial hospital…

What could go right

  • Rising drug-resistant infections
  • Partner royalty/milestone payments

What could go wrong

  • Reliance on partner commercialization
  • Pipeline concentration risk

Moat: narrow (IP / patents, regulatory licence). Patent-protected hospital anti-infectives approved and marketed across multiple markets.

Headquarters: Basel, Switzerland · Founded: 2000 · Employees: 189

Named competitors

Basilea Pharmaceutica at a glance

Size Basilea Pharmaceutica (BSLN.SW) is a Switzerland Health Care company (Pharmaceuticals: Major) with a market value of $1.04B, the 120th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 71.50 on 18 Nov 2026.

Performance Over six months the shares gained 33.4%, against -10.6% for the median peer and +9.3% for the Switzerland market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 4.7% over the last twelve months (peer median +3.1%); the operating margin is 23.9% (peer median 8.0%).

Valuation It trades at 10.5× forward earnings against a peer median of 16.2× (5th cheapest of 15).

Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -18 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 63.0 points above its cost of capital (5.0% WACC).

Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026BSLN.SW 134Peer median 92
Six months, rebased to 100: Basilea Pharmaceutica against the median of its 20 peers (local-currency closes).

Basilea Pharmaceutica financials

Reported figures in CHF; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCHF 247MCHF 232MCHF 209MCHF 158MCHF 148M
Revenue growth—+11%+32%+7%—
Gross profitCHF 217MCHF 193MCHF 170MCHF 131MCHF 121M
EBITDACHF 63.6MCHF 55.3MCHF 64.7MCHF 22.7MCHF 19.4M
Net incomeCHF 52.4MCHF 40.2MCHF 77.6MCHF 10.5MCHF 12.1M
Free cash flowCHF 55.3MCHF 59.5MCHF 72.7MCHF 13.4MCHF 3.92M
Capital expenditureCHF 2.89MCHF 2.86MCHF 1.79MCHF 1.03MCHF 3.30M
Total debtn/aCHF 89.2MCHF 112MCHF 129MCHF 187M

Quarterly statements and history in the cockpit →

Basilea Pharmaceutica competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%-20%-10%0%SVRA600789BLUEJET002737195245536885133004973007020006504887OMER600812688091605116688710MEDCLPYCVETOBSLN.SW6-month return →1-month return →
Up and to the right = strong over both horizons. Basilea Pharmaceutica is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%+200%20×40×60×BLUEJET002737195245536885133004973007020006504887688710BSLN.SWRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Basilea Pharmaceutica is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%600789BLUEJET0027374553300497300702000650600812605116688710VETOBSLN.SWGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Basilea Pharmaceutica is the large dot.

Basilea Pharmaceutica competitors and peer comparison

Head to head with its named competitors (BSLN.SW vs PFE vs MRK vs GILD)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Basilea Pharmaceutica BSLN.SW$1.04B+33%+5%24%10.5×-5.6%
Pfizer PFE$160B+9%+1%26%9.9×-4.3%
Merck & MRK$340B+23%+5%18%16.4×8.3%
Gilead Sciences GILD$210B+30%+7%38%19.9×-2.4%

How Basilea Pharmaceutica compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Basilea Pharmaceutica against its 20 peers (data as of 18 Nov 2026)
MeasureBSLN.SWPeer medianRank in peer set
1-month return+5.9%-5.9%3rd highest of 21
6-month return+33.4%-10.6%highest of 21
Distance from 52-week high-5.7%-32.1%2nd highest of 21
Revenue growth (TTM)+4.7%+3.1%9th highest of 18
Operating margin23.9%8.0%4th highest of 19
Forward P/E10.5×16.2×5th cheapest of 15
Growth the price implies (Req g, 7 yrs)-5.6%2.3%3rd least demanding of 14
Growth delivered (Del g)+12.7%+4.2%4th highest of 14
Hurdle (Req g minus delivered)-18.3 pp-3.3 pp2nd least demanding of 14
ROIC minus cost of capital+63.0 pp+0.1 pphighest of 19
EV / EBITDA12.4×7.3×2nd most expensive of 5
Net debt / EBITDA-1.4×-1.3×3rd least indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Basilea Pharmaceutica BSLN.SWSwitzerland$1.04B+33%+5%24%10.5×-5.6%+12.7%
Savara SVRAUnited States$1.04B-7%n/an/an/an/an/a
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%n/a2.5%+6.5%
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%30.6×40.8%+13.8%
Sunflower Pharmaceutical 002737.SZChina$1.04B-11%+31%-7%4.7×-6.5%-7.7%
Everest Medicines 1952.HKHong Kong$1.05B-20%+193%-5%23.2×n/an/a
Towa Pharmaceutical 4553.TJapan$1.03B-10%+7%9%7.7×-0.3%+12.1%
Chengdu Easton Biopharmaceuticals 688513.SSChina$1.03B-33%-2%13%24.6×4.4%+7.7%
Jiangxi Fushine Pharmaceutical 300497.SZChina$1.02B-23%+103%24%9.9×7.5%-4.5%
Zhejiang Tianyu Pharmaceutical 300702.SZChina$1.02B+1%+27%4%21.4×4.3%+3.5%
Renhe Pharmacy 000650.SZChina$1.01B-12%-7%14%16.9×-10.7%-7.0%
SAWAI 4887.TJapan$1.01B-18%+2%9%12.0×n/an/a
Omeros OMERUnited States$1.08B+24%n/a-56%4.3×n/an/a
North China Pharmaceutical 600812.SSChina$1.08B-12%-21%5%n/a1.0%-4.2%
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%n/an/an/a
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%13.6×-2.0%+18.7%
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%59.3×12.7%+19.4%
MedinCell MEDCL.PAFrance$1.09B+4%-23%-131%n/an/an/a
PYC Therapeutics PYC.AXAustralia$1.09B+29%n/an/an/an/an/a
Jiangsu Kanion Pharmaceutical 600557.SSChina$989M-9%+8%7%19.8×2.3%+1.8%
Vetoquinol VETO.PAFrance$1.10B+19%-1%15%15.5×-3.6%+4.2%

Questions

Who are Basilea Pharmaceutica's main competitors?
Named competitors: Pfizer (PFE), Merck & Co (MRK), Gilead Sciences (GILD). The cockpit's measured peer set (industry) also includes Savara (SVRA), Shandong Lukang Pharmaceutical (600789.SS), Blue Jet Healthcare (BLUEJET.NS), Sunflower Pharmaceutical (002737.SZ), Everest Medicines (1952.HK), Towa Pharmaceutical (4553.T).
Is Basilea Pharmaceutica expensive compared with its peers?
On forward p/e it trades at 10.5× against a peer median of 16.2×, 5th cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -18 pp: the price already allows for a slowdown.
How has Basilea Pharmaceutica stock performed?
Over six months to 18 Nov 2026 the shares returned +33.4% against -10.6% for the median peer; over one year +52.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.